Why Surgical Site Infection Control Is Expanding
The Global Surgical Site Infection Control Market is projected to grow from USD 5.94 billion in 2025 to USD 8.88 billion by 2035, registering a CAGR of 4.1% over the 2026–2035 forecast period, per Market Research Future data. This growth trajectory reflects a structural shift in how healthcare systems value infection prevention: from a cost center to a revenue-protection imperative.
The U.S. Centers for Medicare & Medicaid Services (CMS) Hospital-Acquired Condition Reduction Program penalizes the lowest-performing 25% of hospitals by withholding up to 1% of total Medicare reimbursements—a punitive framework that has made SSI reduction a board-level priority in U.S. acute care. With over 310 million major surgical operations performed annually worldwide per WHO estimates, every incremental procedure creates demand for sterile surgical field maintenance, perioperative antibiotic prophylaxis, and post-operative wound infection prevention consumables.
The aging of populations complicates this demand engine. The United Nations estimates that by 2050 the global population of 65 years and above would be 1.6 billion . above individuals are more prone to SSI due to immunosenescence and the presence of comorbidities such as diabetes. Both orthopedic and cardiovascular operations are focused on senior populations and have SSI rates of 2% to 5% and hence are important targets for SSI reduction methods. Disinfectants hold the largest market share of around 34% due to the universal need across all surgical settings, whereas wound-care devices are the fastest growing segment with a 4.8% CAGR owing to clinical data showing that negative-pressure wound therapy can reduce SSI rates in high-risk procedures.
North America has the largest share of the market at around 38% and is expected to continue to dominate the market due to CMS penalty avoidance and high healthcare spending per capita, while the Asia-Pacific region is the fastest-growing region with an estimated CAGR of 5.3%, driven by hospital construction in China and expanding healthcare access programs in India.
What Structurally Separates Leaders from the Field
MRFR identifies three structural factors that define category leadership in the Surgical Site Infection Control Market: vertical integration across the perioperative continuum—from skin antisepsis through instrument sterilization to wound closure; regulatory and clinical evidence depth that converts product features into hospital accreditation currency; and geographic manufacturing proximity that insulates supply chains from tariff and disruption risk.
Companies that own multiple touchpoints in the SSI prevention pathway—such as STERIS, which controls instrument reprocessing, OR decontamination, and surgical consumables—can offer bundled compliance solutions that single-product competitors cannot match. Meanwhile, the shift from fee-for-service to value-based reimbursement is transforming procurement logic: hospitals under CMS's Bundled Payments for Care Improvement Advanced (BPCI-A) program now cover clinical episodes where infection-free surgical episodes earn bonus payments, creating direct financial returns on sterile surgical field maintenance investments.
Top 10 Global Surgical Site Infection Control Companies — MRFR Rankings (2026)
MRFR has identified and profiled the following leading surgical site infection control companies globally, evaluated on the basis of revenue performance, geographic presence, product breadth, technology strategy, innovation investment, and clinical evidence base. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of July 2026.
|
# |
Company |
HQ |
Revenue (Validated) |
Geographic Presence |
Key Specialization |
Notable Highlight |
|
1 |
Solventum |
St. Paul, MN, USA |
USD 2.93B — Infection Prevention & Surgical Solutions segment (FY2025, Solventum 10-K) |
100+ countries |
Skin antiseptics, surgical drapes, patient warming |
Spun off from 3M April 2024; pure-play infection prevention entity |
|
2 |
BD |
Franklin Lakes, NJ, USA |
USD 21.84B total company (FY2025, SEC 10-K) |
190+ countries |
ChloraPrep skin prep, antimicrobial catheters, Surgiphor wound irrigation |
Divested surgical instrumentation to STERIS for $540M (Aug 2023) to simplify portfolio |
|
3 |
Johnson & Johnson |
New Brunswick, NJ, USA |
USD 94.2B total / USD 33.8B MedTech (FY2025, SEC 10-K) |
60+ countries |
Antimicrobial sutures (VICRYL Plus), wound closure, surgical staplers |
VICRYL Plus meta-analysis shows 30% relative SSI reduction in abdominal/orthopedic procedures |
|
4 |
Mölnlycke Health Care |
Gothenburg, Sweden |
EUR 2.10B total company (FY2025, Annual Report) |
100+ countries |
Biogel surgical gloves, Mepore wound dressings, Granudacyn cleansing |
Acquired P.G.F. Industry Solutions (Granudacyn) for EUR 12M (2024); $135M Brunswick, Maine expansion underway |
|
5 |
STERIS plc |
Dublin, Ireland |
USD 5.94B total continuing operations (FY2026, SEC 8-K/Press Release) |
100+ countries |
Instrument reprocessing, OR decontamination, surgical consumables |
Acquired BD surgical instrumentation assets for $540M (Aug 2023); $60M Mentor, OH sterility assurance plant |
|
6 |
Getinge AB |
Gothenburg, Sweden |
SEK 35.0B total company (~USD 3.3B) (FY2025, Annual Report) |
135+ countries |
Surgical workflow solutions, sterilization systems, sterile transfer |
Acquired Healthmark Industries (~$320M, Oct 2023) and Paragonix Technologies (~$253M upfront, up to $477M total, Sep 2024) |
|
7 |
B. Braun Melsungen |
Melsungen, Germany |
EUR 9.40B total company (FY2025, Annual Report) |
60+ countries |
Disinfectants (Prontosan), wound management, infusion therapy |
Family-owned; EUR 584M R&D spend (6.2% of sales); 66,821 employees |
|
8 |
Cardinal Health |
Dublin, OH, USA |
USD 222.6B total / USD 12.6B Global Medical Products (FY2025, SEC 10-K) |
30+ countries |
Surgical gowns, drapes, procedure kits, distribution |
Largest U.S. distributor of surgical consumables; GMPD segment profit up 47% YoY to $135M |
|
9 |
Medline Industries |
Northfield, IL, USA |
USD 28.4B (FY2025, SEC S-1/Press Release) |
100+ countries |
Surgical prep kits, sterile disposables, fluid temperature management |
Completed IPO Dec 2025 (Nasdaq: MDLN); acquired Ecolab surgical solutions (2024) |
|
10 |
PDI Healthcare |
Orangeburg, NY, USA |
Undisclosed (private) |
Primarily North America |
Surface disinfectant wipes, Sani-HyPerCide, pre-op skin prep |
Subsidiary of Nice-Pak Products; focused exclusively on infection prevention consumables |
*Rankings reflect MRFR's qualitative assessment of scale and market influence in the surgical site infection control sector. Revenue figures are drawn from SEC filings and official investor disclosures where the company is publicly traded; figures for private companies are marked as undisclosed since none of the private companies profiled publish audited segment revenue publicly. Segment revenue is cited where available and materially relevant to SSI control; total company revenue is cited where segment-level data is not publicly disclosed.
Detailed Company Profiles
1. Solventum (legacy 3M Healthcare) | NYSE: SOLV | St. Paul, Minnesota, USA
According to its SEC Form 10-K filing, Solventum’s April 2024 separation from 3M formed a pure-play infection prevention and surgical solutions company with $2.93 billion in dedicated segment revenue for FY2025. Solventum may now focus R&D and M&A firepower on the perioperative antisepsis and sterile field maintenance spaces, free from the capital allocation tug-of-war between 3M’s industrial and consumer portfolios.
Its DuraPrep surgical skin preparation and Bair Hugger warming devices are entrenched in CMS compliance standards, giving Solventum price advantage in a sector where penalty avoidance justifies premium procurement. The company reported net revenues for FY2025 were $8.33 billion in total.
2. BD (Becton Dickinson) | NYSE: BDX | Franklin Lakes, New Jersey, USA
In August 2023, BD sold its surgical instruments platform to STERIS for $540 million, a move that was a planned portfolio consolidation under the BD 2025 strategy, not a withdrawal from surgery. BD sharpened its surgical focus in high-margin, differentiated drug-device combos such as the CE mark-approved BD Surgiphor surgical wound irrigation system launched in select European countries in November 2025 by shedding V. Mueller, Snowden-Pencer and Genesis product lines.
BD has worldwide revenues in FY2025 of $21.84 billion, as per its SEC Form 10-K. BD’s other SSI importance is in the antimicrobial skin preparation and pharmaceutical antiseptic adjacencies where its scale and regulatory obstacles to entry is significant.
3. Johnson & Johnson (Ethicon) | NYSE: JNJ | New Brunswick, New Jersey, USA
J&J's Ethicon division commands the antimicrobial suture category through VICRYL Plus (triclosan-coated polyglactin), which carries the broadest clinical trial base for SSI reduction—meta-analyses demonstrate a 30% relative risk reduction across abdominal and orthopedic procedures.
With J&J MedTech generating $33.8 billion in FY2025 sales within a $94.2 billion total company, per its SEC Form 10-K, the suture franchise is a small revenue line but a massive strategic lever: hospitals bundling J&J sutures into orthopedic and colorectal protocols create switching costs that commodity competitors cannot displace.
4. Mölnlycke Health Care | Private (Investor AB) | Gothenburg, Sweden
Mölnlycke's EUR 12 million acquisition of P.G.F. Industry Solutions in 2024 brought Granudacyn wound cleansing manufacturing in-house, but the more consequential capital allocation is the $135 million (EUR 115 million) U.S. expansion in Brunswick, Maine, announced June 2025, and the new Changshu, China facility.
As a private company owned by Investor AB, Mölnlycke can deploy capital to wound care manufacturing capacity without quarterly earnings pressure. The company reported FY2025 annual sales of EUR 2.10 billion with a 28% EBITDA margin, per its Annual Report 2025. Its Biogel surgical gloves and Mepore post-operative dressings are premium products in a market where CMS penalties make product consistency a board-level priority.
5. STERIS plc | NYSE: STE | Dublin, Ireland
STERIS's $540 million purchase of BD's surgical instrumentation assets in August 2023 added 20,000 SKUs, three manufacturing facilities, and sterilization container expertise that links instrument reprocessing to OR workflow. With FY2026 total continuing operations revenue reaching $5.94 billion, per its SEC 8-K and press release, STERIS is the only top-tier player that owns the full loop from instrument decontamination through surgical draping to terminal sterilization. The company is also investing approximately $60 million in a new sterility assurance manufacturing plant in Mentor, Ohio, expected operational by late 2027, per local news reports.
6. Getinge AB | OMX: GETI B | Gothenburg, Sweden
The acquisition of Healthmark Industries by Getinge in October 2023 for about $320 million and the decision to discontinue the low-margin Surgical Perfusion product category in 2025 reflect a conscious move toward recurring-revenue infection control consumables. Getinge (Annual Report 2025) is revamping its portfolio to focus on sterile transfer and decontamination goods that produce annuity-like income streams, with net sales of SEK 35.0 billion (~USD 3.3 billion) in FY2025. Acquired Paragonix Technologies in September 2024 for ~ $253 million cash upfront (total deal value up to $477 million including earn-outs) to expand its transplant care ecosystem.
7. B. Braun Melsungen | Private (family-owned) | Melsungen, Germany
As one of the few remaining large family-owned medtech manufacturers, B. Braun reported consolidated sales of EUR 9.40 billion in FY2025, per its Annual Report 2025, with 66,821 employees and EUR 584 million in R&D expenditure (6.2% of sales).
Its Prontosan wound irrigation and disinfectant lines benefit from vertical integration across European manufacturing and a distribution network that reaches into emerging markets where public hospital procurement favors long-term supplier relationships. The company operates in more than 60 countries with proprietary production in multiple European and Asian facilities.
8. Cardinal Health | NYSE: CAH | Dublin, Ohio, USA
Cardinal is very pharmaceutical, with $222.6 billion in revenue in FY2025, but its Global Medical Products and Distribution (GMPD) sector at $12.6 billion is the top surgical gown, drape, and procedure kit distributor in the U.S., according to its SEC Form 10-K.
The strategic dilemma is that Cardinal’s SSI control products are high volume/low margin commodities in a pharma dominant portfolio. The FY2025 GMPD sector earnings was up 47% YoY to $135 million, illustrating operational improvement, but the segment’s 1.07% profit margin indicates the pricing pressure typical of distribution-led models.
9. Medline Industries | Nasdaq: MDLN | Northfield, Illinois, USA
Medline’s December 2025 IPO and $28.4 billion in FY2025 net sales signal a transition from private-equity portfolio firm to public-market growth stock, according to its SEC S-1 filing and press release. Ecolab’s purchase of its surgical solutions company in 2024 brought Microtek sterile drapes and fluid temperature-management systems, directly targeting the ASC market migration.
Medline’s publicly published balance sheet contains $3.5 billion in FY2025 Adjusted EBITDA and $2.4 billion in new client signings to integrate fragmented surgical disposable makers. The corporation runs more than 20 manufacturing sites, most of them in North America.
10. PDI Healthcare | Private (Nice-Pak Products) | Orangeburg, New York, USA
PDI Healthcare operates as a Nice-Pak Products subsidiary focused exclusively on infection prevention consumables, including the Sani-HyPerCide surface disinfectant line and pre-operative skin prep portfolio. PDI competes not on scale but on clinical protocol intimacy—its advantage is the ability to customize compliance programs for individual hospital infection prevention departments without the corporate overhead of diversified medtech conglomerates. The company serves primarily the North American market. Revenue and employee figures are not publicly disclosed.
M&A Activity Tracker (2023–2025)
The Surgical Site Infection Control Market has experienced targeted consolidation as operators pursue inorganic growth to capture the converging instrument reprocessing, surgical consumable, and perioperative antisepsis markets. Market Research Future tracks the following verified, named transactions directly relevant to the SSI control market; entries that could not be corroborated against a dated public source have been removed rather than retained as unverified placeholders.
|
Year |
Acquirer |
Target |
Deal Value |
Strategic Objective |
|
2023 |
STERIS plc |
BD Surgical Instrumentation platform (V. Mueller, Snowden-Pencer, Genesis) |
USD 540M |
Added 20,000 SKUs and sterilization container expertise to close the loop between instrument reprocessing and OR workflow, creating single-source accountability for SSI outcomes |
|
2024 |
Medline Industries |
Ecolab Global Surgical Solutions (Microtek drapes, surgical products) |
Undisclosed |
Captured ASC procedural migration with integrated sterile drape and temperature-management bundles, expanding Medline Brand beyond commodity disposables |
|
2024 |
Mölnlycke Health Care |
P.G.F. Industry Solutions GmbH (Granudacyn wound cleansing) |
EUR 12M |
Vertically integrated hypochlorous-acid wound cleansing manufacturing to support post-operative incision care and expand reach beyond 100-country distribution network |
|
2023 |
Getinge AB |
Healthmark Industries (sterilization monitoring, infection control consumables) |
USD ~320M |
Bolstered sterile processing consumables portfolio within Surgical Workflows, capturing recurring revenue from compliance-intensive reprocessing departments |
|
2024 |
Getinge AB |
Paragonix Technologies (organ transport/preservation) |
USD ~253M upfront (up to $477M total with earn-outs) |
Extended transplant care and surgical workflow ecosystem with organ preservation technology, complementing sterile transfer capabilities |
MRFR analysis identifies vertical integration of instrument reprocessing, surgical consumables, and sterilization monitoring as the dominant M&A theme in the SSI control market. STERIS's acquisition of BD's surgical instrumentation assets and Medline's absorption of Ecolab's surgical solutions business illustrate a market-wide shift toward perioperative platform consolidation—hospitals under value-based purchasing increasingly demand single-vendor accountability across the entire sterile surgical field maintenance continuum.
R&D Investment & Innovation Signals
To address the key operational challenges of avoiding CMS penalties, antimicrobial resistance, and supply chain resilience, companies in the Surgical Site Infection Control market are concentrating on next-generation antiseptics, automated sterilization compliance, advanced wound closure materials, and digital perioperative workflow platforms.
-
Solventum continues to invest in its Infection Prevention and Surgical Solutions segment, which generated $2.93 billion in FY2025, reflecting sustained R&D in perioperative antisepsis and patient warming protocols that reduce hypothermia-related SSI risk.
-
BD launched the BD Surgiphor Surgical Wound Irrigation System in Europe in November 2025, receiving CE mark approval as the first-of-its-kind sterile, ready-to-use irrigation solution designed to reduce bacterial load in surgical wounds—positioning BD in the high-margin pharmaceutical-antiseptic adjacency rather than commodity hardware.
-
STERIS is investing approximately $60 million in a new sterility assurance manufacturing plant in Mentor, Ohio, scheduled for operational launch by late 2027, per local news reports—consolidating U.S. production to support long-term demand from customers under tightening CMS compliance frameworks.
-
Mölnlycke earned EcoVadis Platinum for the second consecutive year in 2025 and was named to LinkedIn's Top Companies list in Sweden, but its R&D spending at 2.7% of revenue remains below the 5–7% MedTech norm—raising questions about whether its Safetac technology moat can endure against lower-cost Chinese foam dressing manufacturers.
-
J&J Ethicon continues to generate clinical evidence for VICRYL Plus antimicrobial sutures, with meta-analyses showing 30% relative SSI reduction, using regulatory and clinical evidence as a competitive weapon to command bundled pricing power in orthopedic and colorectal protocols.
-
Getinge received CE mark reinstatement for its Cardiosave intra-aortic balloon pump in August 2025 and achieved multiple new EU MDR approvals, demonstrating that its quality remediation investments are translating into regulatory momentum.
-
Cardinal Health reported a 47% year-over-year increase in Global Medical Products and Distribution segment profit for FY2025 to $135 million, reflecting operational efficiency investments rather than product innovation—a signal that Cardinal's SSI strategy remains distribution-scale dependent rather than clinically differentiated.